Valion Bio (VBIO) EBIT Growth (1y) (2022 - 2026)
Valion Bio (VBIO) EBIT Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | 10.14% |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 269.85% |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | 1,528.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -336.63% |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | 99.51% |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | -36.55% |
| 10 | Valion Bio | 418,443.64 | -1.78 Mn | -45,000.00 | 97.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.67% |
| Dec 31, 2025 | 104.92% |
| Sep 30, 2025 | -73.52% |
| Jun 30, 2025 | -52.76% |
| Mar 31, 2025 | -1.69% |
| Dec 31, 2024 | 33.91% |
| Sep 30, 2024 | 18.69% |
| Jun 30, 2024 | 40.42% |
| Mar 31, 2024 | 30.01% |
| Dec 31, 2023 | 0.53% |
| Sep 30, 2023 | 31.89% |
| Jun 30, 2023 | 29.59% |
| Mar 31, 2023 | 5.58% |
| Dec 31, 2022 | 1.57% |
| Sep 30, 2022 | -110.25% |
| Jun 30, 2022 | -186.07% |
| Mar 31, 2022 | -112.02% |